The histone deacetylase inhibitor valproic acid sensitizes human and canine osteosarcoma to doxorubicin.

ABSTRACT:

Purpose

Osteosarcoma (OS) remains an incurable and ultimately fatal disease in many patients, and novel forms of therapy are needed. Improved models of OS that more closely mimic human disease would provide more robust information regarding the utility of novel therapies. Spontaneous OS in dogs may provide such a model. Pharmacologic inhibition of histone deacetylase (HDAC) enzymes has a variety of anti-tumor effects but may demonstrate the most utility when utilized in combination with standard cytotoxic therapies. We sought to determine the in vitro and in vivo effects of the HDAC inhibitor valproic acid (VPA) on doxorubicin (DOX) sensitivity in canine and human OS.

Methods

We evaluated the in vitro anti-proliferative and apoptotic effects of VPA/DOX combination treatment,

SUBMITTER: Wittenburg LA 

PROVIDER: S-EPMC2916050 | biostudies-literature | 2011 Jan

REPOSITORIES: biostudies-literature